Introduction
The development of gonadotrophin-releasing hormone (GnRH) antagonists has led to a number of attempts to use these analogues to induce azoospermia. However, administration of large doses has led to undesirable side effects. Daily injection or continuous infusion of milligram doses of GnRH antagonists for 9 weeks induced azoospermia in male monkeys, but was associated with a signifi¬ cant loss of body weight (Weinbauer et al, 1984; Akhtar et al, 1985) . Subcutaneous administration of large doses of the antagonist, Ac-(2)D-NAL1-pF-D-Phe2-D-Trp3-D-Arg6-GnRH, caused facial oedema and oedema of the extremities in rats and reduced spontaneous activity in monkeys (Schmidt et al, 1984) . These results suggested that it might be impossible to attain reliable azoos¬ permia without significant side effects, thus reducing the possibility of using GnRH antagonists for contraception.
However, the provision of low levels of GnRH agonist by continuous infusion is an effective way of suppressing LH and testosterone secretion and the response to a GnRH challenge (Akhtar et al, 1983; Mann et al, 1984) . In this study, we examine the effect of continuous infusion of a GnRH antagonist via osmotic minipump on basal LH and testosterone secretion and the response to an i.v. bolus of GnRH in male rhesus monkeys. In addition, we investigated the effect of lowdose continuous infusion of GnRH antagonist treatment on sperm count and quality. (LER 1909-2) as the reference preparation. The intra-and interassay coefficients of variation were 14-1 and 14-7% respectively. The minimal detectable dose for LH was 0-2 pg/ml. Serum coricentrations of testosterone were determined by radioimmunoassay as previously described (Perachio et al, 1977) . The intra-and interassay coefficients of variation for testosterone were 5-1 and 6-8%. The minimal level of detection for the testosterone assay was 0-5 ng/ml. Testicular measurements were made at monthly intervals with Lange calipers with a compression pressure of 15 g as previously described (Mann et al, 1985) . The formula used for testicular volume was 4/3 a2b (a = short axis; b = long axis). Testicular needle biopsies were performed on all animals during the pretreatment period, at the end of antagonist treatment and at 16 weeks of recovery. Tissue was processed for routine histological examination as previously described (Mann et al, 1985) . Biopsy samples were embedded in paraffin wax, cut at 4 pm and stained with haematoxylin and eosin or with Masson's trichrome for connective tissue. The mean + s.e.m. of the number of seminiferous tubules collected from biopsies was 34-6 + 4-7 (range 10-47).
Animals were subjected to rectal probe ejaculation at approximately 4-week intervals as reported previously (Gould et al, 1978) (1976) . Hamster oocytes were recovered from superovulated hamsters (25 i.u. PMSG i.p. followed by 50 i.u. hCG i.p. 3 days later). The cumulus cells were removed by incubating in 1 % hyaluronidase for 15 min and the zonae were dissolved by transferring the oocytes to a 0-1 % trypsin solution in Dulbecco's medium for 10 min. After dissolution of the zonae pellucidae, the denuded oocytes were transferred to Ham's FIO medium containing 10% human cord serum. After washing, 10 oocytes were cultured in 0-5 ml culture medium in each well of an 8-well culture dish (Lab Tek, Inc., Naperville, IL).
Semen samples were washed twice in culture medium, concentrated by centrifugation and further washed by allowing motile spermatozoa to 'swim up' into Ham's culture medium which had been overlaid on the sperm pellet. The 'swim-up' procedure took 30-60 min. Washed spermatozoa were added to the denuded oocytes at a ratio of 25 000 motile spermatozoa/oocyte, and 10-30 oocytes were used per assay. Incubations were performed at 37°C. At 18 h the oocytes were compressed under a cover slip and stained with aceto-orcein or lacmoid. The assay was scored according to the percentage of oocytes penetrated per well. After penetration, the sperm head undergoes swelling and decondensation, and can be identified by using phase-contrast microscopy.
The statistical significance of all results, except those from the hamster ova penetration assay, was assessed by analysis of variance and the least significant difference for multiple comparisons as needed (Keppel, 1973 (Fig. 3a) , from 7-1 + 2-4 108/ml during the pretreatment period to 0-29 108/ml during the last month of antagonist infusion. The percentages of motile and live spermatozoa in ejaculates (Fig. 3b) also decreased during the treatment period, but not statistically significantly so.
During the final month of antagonist treatment, spermatozoa from treated monkeys showed a reduced ability (P < 0005) to penetrate denuded hamster ova (Fig. 4) Fig. 1 ).
In the antagonist-treated monkeys, active spermatogenesis persisted, as indicated by the presence of germ cells representative of all stages of spermatogenesis, including spermatids (Fig. 5) , but though present, spermatids were less numerous than in pretreatment biopsies. There was no thickening of the lamina propria, or other evidence of intertubular fibrosis. No areas of calcification were noted.
The testicular volumes of the 4 animals treated with the GnRH antagonist are shown in Fig. 6 . Testicular volumes declined more than 45% in the 4 monkeys during antagonist treatment. In Monkey B, in which it was not possible to maintain suppressed concentrations of serum LH and testosterone (see Fig. 1 ), testicular volume increased between 5 and 8 months of antagonist treatment before declining again.
The mean + s.e.m. of pretreatment body weights (8-9 + 0-5 kg) did not differ from body weights (9-4 + 0-6 kg) at the end of treatment. None of the 4 monkeys lost weight over the course of antagonist administration. We did not observe any effect of antagonist treatment on spontaneous activity nor was there any noticeable peripheral or facial oedema in the monkeys. 
Discussion
The inhibitory effect of GnRH antagonists on gonadal function apparently relates to their ability to bind with high affinity to pituitary GnRH receptors, preventing binding by native GnRH (Clayton et al, 1982) . There is no evidence that antagonists alter the turnover rate of the GnRH receptor (Bex & Corbin, 1984) . In the present study, serum LH and testosterone concentrations showed an immediate fall with the onset of antagonist treatment, but then recovered toward pretreatment values after 8-10 weeks of antagonist administration (100 µg/day). This recovery may result from compensation by the hypothalamus and/or pituitary to the reduced levels of LH, and increased sensitivity of the pituitary to GnRH. Our data support this mechanism. During the periods that LH and testosterone showed recovery during antagonist treatment, the serum LH response to GnRH was supernormal. Furthermore, the serum testosterone response to GnRH was elevated above the pretreatment response throughout antagonist administration, suggesting increased sensitivity of the gonads to LH in the presence of reduced serum concentrations of gonadotrophin.
Two other explanations are possible for the recovery from antagonist treatment. It is possible that antibodies against GnRH were generated, leading to a reduced suppression. This is unlikely from this small decapeptide, although it cannot be excluded because of its highly modified nature relative to native GnRH. A second possibility is that the GnRH antagonist loses its potency during the 4 weeks it is present in the minipump. This explanation can be excluded by the fact that serum LH and testosterone concentrations were not suppressed again when pumps were replaced, but only by increased levels of the GnRH antagonist.
While there was suppression of LH and testosterone in some animals with continuous low doses of the antagonist, the suppression was not complete and serum LH and testosterone values tended to increase after a period of treatment. These results clearly suggest that the mechanism for inhi¬ bition by GnRH antagonists is very different from the continuous administration of small amounts of a GnRH agonist. Agonist treatment leads to initial stimulation of LH followed by down regu¬ lation of the GnRH receptor and marked suppression of LH concentrations (Heber & Swerdloff, 1981) . On the other hand, the antagonists suppress LH by a receptor occupancy mechanism (Clayton et al, 1982) .
At the doses of antagonist used in this study, we did not encounter the side effects reported by previous workers (Schmidt et al, 1984; Weinbauer et al, 1984; Akhtar et al, 1985) ). Two different p-Cl-Phe2-D-Trp3-D-Arg(Et2)6-D-Ala10-GnRH) caused a significant loss of weight when adminis¬ tered in daily doses sufficient to induce azoospermia (Weinbauer et al, 1984; Akhtar et al, 1985) . The antagonist used in this study was the same analogue which caused oedema in rats and reduced spontaneous activity in monkeys (Schmidt et al, 1984 (Schmidt et al, 1984; Weinbauer et al, 1984; Akhtar et al, 1985) or loss of ejaculatory response.
Our results show that continuous infusion of 100-400 µg/day of a GnRH antagonist caused oligospermia, although azoospermia was not achieved. These results contrast with those of pre¬ vious studies in which doses 5-10-fold higher did induce azoospermia (Weinbauer et al, 1984; Akhtar et al, 1985) . Additional studies with a higher dose of GnRH antagonist administered by continuous infusion will be necessary to determine whether a dose of GnRH antagonist can be identified which gives azoospermia without undesirable side effects or loss of ejaculatory response. Our study suggests that it may be possible to achieve reliable contraception without attaining azoospermia. Spermatozoa from GnRH antagonist-treated animals penetrated only 6% of denuded hamster ova versus 27% by spermatozoa from untreated animals, suggesting that GnRH antagonist-treated male monkeys have a reduced fertilizing potential.
